BioPharm International Editors

The Natural Product Center of Excellence seeks to identify novel active compounds for new antibiotics.

J&J's diagnostics business goes to global asset manager, The Carlyle Group.

The Stevens Institute of Technology will open a new biotechnology laboratory in January 2014.

Combined technologies from Agilent Technologies and Picometrics Technologies are designed for large–molecule analysis.

Novasep selects Thierry van Nieuwenhove as new president of the synthesis business unit.

Lonza signs an agreement with Index Ventures for the development and manufacture of biologics for portfolio companies.

USP opens expanded Shanghai facility to enhance quality standards for medicines and food ingredients.

CCBR–SYNARC and BioClinica merge to create a provider of specialized outsourced clinical services.

A packaging defect has led to Merck voluntarily recalling all lots of Liptruzet tablets in the United States.

USP announced the approval of General Notices section 5.60.30 Elemental Impurities in USP Drug Products and Dietary Supplements with an official date of Dec. 1, 2015.

CytomX Therapeutics and ImmunoGen announce collaboration to develop probody-drug conjugate therapies for the treatment of cancer.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

MedImmune has entered into a research collaboration with Immunocore to develop novel cancer therapies.

LSNE completes an FDA inspection of its Manchester manufacturing facility.Lyophilization Services of New England (LSNE),

FDA releases guidance on developing drugs for the treatment of community-acquired bacterial pneumonia.

Research was published describing a natural interferon-alpha for infection control and treatment of drug-resistant H7N9 influenza.

FDA releases guidance on the qualification of drug development tools.

Zymeworks has entered into a licensing and collaboration agreement with ImClone Systems to develop novel bi-specific antibody oncology therapeutics.

GE acquires Thermo Fisher-s HyClone cell culture media and sera products, gene modulation technologies, and magnetic beads businesses.

Abrams Royal Pharmacy is recalling all unexpired lots of sterile products dispensed in the US.

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Baxter International recalls dextrose injection and four sodium chloride injections.

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.

Merck and GlaxoSmithKline begin clinical trial of pazopanib for the treatment of advanced renal-cell carcinoma.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Pfizer appoints management changes to take effect in 2014.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.